Zealand Pharma AS News - 22Z

Zealand Pharma major shareholder announcement: Van Herk Investments

Zealand Pharma major shareholder announcement: Van Herk Investments Company announcement – No. 38 / 2024 Zealand Pharma major shareholder...

Total number of shares and voting rights in Zealand Pharma at June 28, 2024

Total number of shares and voting rights in Zealand Pharma at June 28, 2024 Company announcement – No. 37 / 2024 Total number of shares and...

Zealand Pharma completes registration of capital increase

Zealand Pharma completes registration of capital increase Company announcement – No. 36 / 2024 Zealand Pharma completes registration of...

Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion

Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion /...

Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion

Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1...

Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion

Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion Company...

Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide

Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin...

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Company announcement – No. 31 / 2024 Zealand...

Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of...

Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL

Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL Company...

Zealand Pharma major shareholder announcement: Polar Capital

Zealand Pharma major shareholder announcement: Polar Capital Company announcement – No. 28 / 2024 Zealand Pharma major shareholder...

Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide

Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist...

Zealand Pharma Announces Financial Results for the First Quarter of 2024

Zealand Pharma Announces Financial Results for the First Quarter of 2024 Company announcement - No. 26 / 2024 Zealand Pharma Announces...

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely...

Correction to Company announcement – No. 23 / 2024

Correction to Company announcement – No. 23 / 2024 Correction to Company announcement – No. 23 / 2024 Copenhagen, Denmark, April 19, 2024 –...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Zealand Pharma AS (22Z)

Professional-Grade Tools, for Individual Investors.

22Z News

Zealand Pharma major shareholder announcement: Van Herk Investments

Total number of shares and voting rights in Zealand Pharma at June 28, 2024

Zealand Pharma completes registration of capital increase

Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion

Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion

Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion

Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL

Zealand Pharma major shareholder announcement: Polar Capital

Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide

Zealand Pharma Announces Financial Results for the First Quarter of 2024

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Correction to Company announcement – No. 23 / 2024

22Z Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Zealand Pharma AS (22Z) News

Zealand Pharma AS (22Z)

Professional-Grade Tools, for Individual Investors.

22Z News

Zealand Pharma major shareholder announcement: Van Herk Investments

Total number of shares and voting rights in Zealand Pharma at June 28, 2024

Zealand Pharma completes registration of capital increase

Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion

Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion

Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion

Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL

Zealand Pharma major shareholder announcement: Polar Capital

Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide

Zealand Pharma Announces Financial Results for the First Quarter of 2024

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Correction to Company announcement – No. 23 / 2024

22Z Discussion

Your Recent History